See more : GeoPark Limited (GPRK) Income Statement Analysis – Financial Results
Complete financial analysis of Pear Therapeutics, Inc. (PEAR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pear Therapeutics, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Eimco Elecon (India) Limited (EIMCOELECO.BO) Income Statement Analysis – Financial Results
- Trex Company, Inc. (TREX) Income Statement Analysis – Financial Results
- Crescent Capital BDC, Inc. (CCAP) Income Statement Analysis – Financial Results
- PT Mahaka Radio Integra Tbk (MARI.JK) Income Statement Analysis – Financial Results
- H-One Co.,Ltd. (5989.T) Income Statement Analysis – Financial Results
Pear Therapeutics, Inc. (PEAR)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://peartherapeutics.com
About Pear Therapeutics, Inc.
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 12.69M | 4.21M | 9.38M | 32.56M |
| Cost of Revenue | 8.18M | 5.23M | 1.72M | 998.00K |
| Gross Profit | 4.51M | -1.03M | 7.67M | 31.56M |
| Gross Profit Ratio | 35.54% | -24.36% | 81.69% | 96.94% |
| Research & Development | 48.31M | 37.04M | 28.08M | 35.70M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 79.55M | 67.62M | 56.23M | 27.47M |
| Other Expenses | 0.00 | -2.05M | -16.82M | 544.00K |
| Operating Expenses | 127.86M | 104.66M | 84.31M | 63.17M |
| Cost & Expenses | 136.04M | 109.89M | 86.03M | 64.17M |
| Interest Income | 0.00 | 0.00 | 0.00 | 1.42M |
| Interest Expense | 3.89M | 0.00 | 2.56M | 0.00 |
| Depreciation & Amortization | -46.05M | -46.74M | 1.43M | -20.10M |
| EBITDA | -169.40M | -152.43M | -75.22M | -51.70M |
| EBITDA Ratio | -1,334.48% | -3,622.27% | -801.52% | -158.79% |
| Operating Income | -123.35M | -105.69M | -76.64M | -31.60M |
| Operating Income Ratio | -971.72% | -2,511.53% | -816.75% | -97.05% |
| Total Other Income/Expenses | 47.86M | 40.54M | -12.17M | 22.27M |
| Income Before Tax | -75.49M | -65.14M | -97.02M | -9.33M |
| Income Before Tax Ratio | -594.70% | -1,548.05% | -1,033.92% | -28.67% |
| Income Tax Expense | -51.75M | -44.85M | 3.56M | -21.73M |
| Net Income | -23.74M | -20.29M | -100.58M | 12.39M |
| Net Income Ratio | -187.02% | -482.27% | -1,071.86% | 38.05% |
| EPS | -0.17 | -0.18 | -0.73 | 0.09 |
| EPS Diluted | -0.17 | -0.18 | -0.73 | 0.09 |
| Weighted Avg Shares Out | 138.71M | 113.33M | 137.80M | 137.80M |
| Weighted Avg Shares Out (Dil) | 138.71M | 113.33M | 137.80M | 137.80M |
Why Pear Therapeutics Stock Is Rising Today
5 Buy-Rated Stocks Trading Under $10 With Huge 2022 New Year's Potential
Source: https://incomestatements.info
Category: Stock Reports